Get the Stockscreener App
6.48
2.56%
-0.17
Fulcrum Therapeutics Inc stock is traded at $6.48, with a volume of 181.41K.
It is down -2.56% in the last 24 hours and down -14.62% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$6.65
Open:
$6.71
24h Volume:
181.41K
Relative Volume:
0.28
Market Cap:
$350.51M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-4.1013
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
-5.81%
1M Performance:
-14.62%
6M Performance:
+92.28%
1Y Performance:
-25.86%
1-Day Range:
$6.40
$6.71
1-Week Range:
$6.35
$6.88
52-Week Range:
$2.315
$9.30
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
6.48 | 359.71M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
Using Ichimoku Cloud for Fulcrum Therapeutics Inc. technicalsNew Guidance & High Conviction Investment Ideas - Newser
Is this a good reentry point in Fulcrum Therapeutics Inc.Quarterly Profit Review & Long Hold Capital Preservation Plans - Newser
Evaluating Fulcrum Therapeutics Inc. with trendline analysisJuly 2025 Big Picture & Safe Capital Growth Trade Ideas - Newser
Fulcrum Therapeutics Inc. stock prediction for this weekWeekly Investment Recap & Fast Moving Market Watchlists - Newser
Fulcrum Therapeutics Inc. stock daily chart insights2025 Investor Takeaways & Daily Technical Stock Forecast Reports - Newser
Applying big data sentiment scoring on Fulcrum Therapeutics Inc.Market Trend Review & Low Risk Profit Maximizing Plans - Newser
Analyzing Fulcrum Therapeutics Inc. with risk reward ratio chartsTreasury Yields & AI Powered Trade Plan Recommendations - Newser
Exit strategy if you’re trapped in Fulcrum Therapeutics Inc.Market Performance Summary & Consistent Growth Stock Picks - Newser
Will Fulcrum Therapeutics Inc. benefit from macro trendsLong Setup & Expert Approved Momentum Trade Ideas - Newser
Combining machine learning predictions for Fulcrum Therapeutics Inc.2025 Trading Volume Trends & Community Trade Idea Sharing - Newser
Will Fulcrum Therapeutics Inc. see short term momentumJuly 2025 Movers & Accurate Intraday Trading Signals - Newser
Market reaction to Fulcrum Therapeutics Inc.’s recent news2025 Trade Ideas & Verified Swing Trading Watchlist - Newser
Using Bollinger Bands to evaluate Fulcrum Therapeutics Inc.2025 Earnings Surprises & Verified Technical Trade Signals - Newser
Real time pattern detection on Fulcrum Therapeutics Inc. stockTrade Ideas & Verified Chart Pattern Trade Signals - Newser
How high can Fulcrum Therapeutics Inc. stock go2025 Growth vs Value & Fast Exit Strategy with Risk Control - Newser
Measuring Fulcrum Therapeutics Inc.’s beta against major indicesJuly 2025 Pullbacks & Free Safe Capital Growth Stock Tips - Newser
Is Fulcrum Therapeutics Inc. meeting your algorithmic filter criteriaIndex Update & High Conviction Buy Zone Alerts - Newser
Is Fulcrum Therapeutics Inc. reversing from oversold territoryMarket Activity Report & Free Technical Confirmation Trade Alerts - Newser
Relative strength of Fulcrum Therapeutics Inc. in sector analysisWeekly Loss Report & Risk Adjusted Swing Trade Ideas - Newser
Building trade automation scripts for Fulcrum Therapeutics Inc.July 2025 Institutional & Long-Term Investment Growth Plans - Newser
Will earnings trigger a reversal in Fulcrum Therapeutics Inc.Rate Cut & Risk Adjusted Buy/Sell Alerts - Newser
How to interpret RSI for Fulcrum Therapeutics Inc. stockJuly 2025 Levels & Real-Time Buy Signal Alerts - Newser
Fulcrum Therapeutics shares fall 1.88% intraday after corporate presentation in August 2025. - AInvest
Chart overlay techniques for tracking Fulcrum Therapeutics Inc.2025 Fundamental Recap & AI Driven Stock Reports - Newser
Is Fulcrum Therapeutics Inc. stock reversal real or fakeJuly 2025 Decliners & High Conviction Buy Zone Picks - Newser
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):